PROSTATE CANCER

This blog is a collection of my favorite new treatments for prostate cancer currently available through clinical trials. The start of each post contains a brief description of the approach, reasons I included it and a link to the trial website.

RANK-ing the Effects of Denosumab in Prostate Cancer Patients with High PSA doubling Times

Metastasis to the bone is a common feature of prostate cancers. When prostate cancers metastasize to the bone, they hijack the bone remodelling process in order to be incorporated into the newly developed bone tissue. Denosumab is a monoclonal… [Learn More…]

New Treatment Extends Life for Men with Advanced Prostate Cancer

Most patients with advanced prostate cancer eventually become resistant to anti-androgen therapy (including bicalutamide therapy). MDV3100 is an advanced drug that blocks multiple processes of androgen signalling including binding of testosterone to… [Learn More…]

Cabozantinib for Castration-Resistant Prostate Cancer

Cabozantinib is a multiple tyrosine kinase inhibitor that blocks the vascular endothelial growth factor receptor (VEGFR) and the receptor of hepatocyte growth factor (C-MET), resulting in significant benefits for patients with metastatic prostate… [Learn More…]

DCVax: Slowing the Progression of Metastatic Prostate Cancer.

Prostate cancer patients whom experience rising PSA levels while on hormone treatment typically progress to metastatic disease on average in about 28-36 weeks. DCVax is a vaccine made from a patient’s own dendritic cells and loaded with a form of… [Learn More…]

Itraconazole: An Antifungal Drug That Delays Need For Chemo In Advanced Prostate Cancer

Itraconazole is an antifungal drug commonly used to treat nail fungus. Recent research has shown that it also disrupts a key cancer-initiating pathway and appears to prevent angiogenesis in prostate cancers. I like this approach because it… [Learn More…]

Cabozantinib: Treatment For Castration-Resistant Prostate Cancer That Has Metastasized To The Bone

Cabozantinib is a drug that inhibits genes involved in tumor growth, invasion, metastasis and angiogenesis (via VEGFR2). In this trial, 74% of the patients had disease regression and some patients had major complete or partial resolution of prostate… [Learn More…]

Androgen-Deprivation Therapy Before And During Radiotherapy Improves Overall Survival In Prostate Cancer

Short-term androgen-deprivation therapy (ADT) before and during radiotherapy improves cancer control and overall survival in patients with early, localized prostate adenocarcinoma. In this study, patients that received radiotherapy plus… [Learn More…]